The administration of large doses of 17a-ethyl-19-nortestosterone to man is frequently associated with hyperbilirubinemia, with conjugated bilirubin in the serum and increased retention of sulfobromophthalein (BSP) in the serum 45 minutes after the intravenous administration of 5 mg BSP per kg body weight (1). Light microscopy studies of hematoxylin-and eosin-stained sections of liver reveal normal liver cells with occasional canalicular bile casts (2). Treatment of rats with 17a-ethyl-19-nortestosterone results in reduced capacity to excrete BSP and conjugated bilirubin in the bile (3). These observations suggest that the steroid may functionally interfere with the excretion of BSP and conjugated bilirubin by the liver cell into the bile. The mechanism by which BSP retention is produced in man has not been established.
The metabolism of BSP by the liver involves uptake and storage of BSP (4) , intracellular formation of a glutathione conjugate (5) (6) (7) , and subsequent excretion of free and conjugated BSP into the bile (5) (6) (7) . The storage of BSP in parenchymal liver cells is directly proportional to the plasma concentration of BSP, whereas the transfer of BSP from the liver cell to bile is by a rate-limiting transfer mechanism (8, 9) . Conjugation of BSP with glutathione is an important determinant of the maximal rate at which BSP is transferred from blood to bile (10, 11) . A method for the simultaneous estimation of hepatic BSP storage and excretion and data regarding its (9) . In the present study, this technique (9) was used to study the effect of 17a-ethyl-19-nortestosterone on BSP metabolism in man.
MATERIALS AND METHODS
Eighteen patients who demonstrated neither clinical evidence of liver disease nor abnormal tests of liver function were selected for study. The following tests of liver function were performed in each patient by using standard procedures: estimation of the concentration of serum albumin, globulin, and bilirubin; electrophoresis of serum proteins; serum cephalin cholesterol and thymol flocculation; serum alkaline phosphatase, glutamic oxaloacetic transaminase, and glutamic pyruvic transaminase activities; and retention of BSP in serum 45 minutes after the intravenous administration of 5 mg BSP per kg body weight.
Ten patients served as controls and did not receive 17a- The relative hepatic BSP storage (S) and transport maximum (Tm) were estimated (9) in ten control sub- I ASA = acetylsalicylic acid.
jects, three patients during steroid administration, three patients before and during steroid administration, and two patients both during and after steroid administration. A Harvard multispeed infusion pump was used to inject BSP at rates of 15, 5, and 10 mg per minute during the three infusion periods before the steroid was administered and at 8, 0, and 5 mg per minute after the steroid was given. The latter rates were selected to avoid potentially toxic reactions to large doses of BSP which could not be metabolized as readily as by normal liver (9) . The concentration of free and conjugated BSP was estimated in plasma obtained at the end of each hour of the BSP infusion before and during steroid administration in two patients (D.T. and J.F.) with the method described by Combes and Stakelum (6) .
Aspiration liver biopsy was performed in two patients (D.T. and J.F.) within 24 hours after the cessation of steroid administration. The liver biopsy specimens were fixed for electron microscopic examination and the following procedures: hematoxylin and eosin, oil red orange and ATPase, acid phosphatase, alkaline phosphatase, and 5-nucleotidase activities.
The tests of liver function were repeated in each patient one week after steroid administration was discontinued.
RESULTS
The results of the BSP infusion studies are presented in Table II . In the control group, the mean relative hepatic storage (S) of BSP was 61 ± 18 (SD) mg of BSP stored per mg BSP per 100 ml plasma and the mean transport maximum (Tm) for BSP was 7.6 ± 1.7 mg BSP excreted per minute. Estimates of S and Tm were within the range of normal in each of the three patients who were studied prior to steroid administration. These three patients and five additional patients were studied during steroid administration, and they demonstrated normal relative hepatic storage of BSP; however, BSP Tm ranged from +.35 to 2.1 mg per minute. BSP Tm returned to normal limits one week after steroid was discontinued in the two patients (A.H. and W.J.) in whom this was studied. The average plasma BSP concentrations during each BSP infusion period before, during, and after administration of 17a-ethyl-19-nortestosterone are presented in Table III .
The ratios of conjugated to total BSP in plasma obtained at the end of each hour of the BSP infusion study in two patients (D.T. and J.F.) before and during steroid administration are presented in Table IV . Prior to steroid administration, the proportion of conjugated to total BSP in plasma increased only when the infusion rate exceeded Tm (i.e., in infusion periods I and III). After steroid administration, the proportion of conju-liver cells probably represent BSP. Histochemical gated to total BSP increased in each infusion pe-findings were normal except for ATPase staining riod. Although no BSP was infused during pe-of bile canaliculi which revealed variable distortion. riod II, the plasma BSP concentration remained Electron microscopy revealed normal cellular archrelatively constant, and almost 90%o of the BSP in itecture. Several bile canaliculi appeared slightly the plasma was in a conjugated form. dilated; however, these changes were variable and Light microscopic examination of hematoxylin-their significance could not be evaluated. Lyso--and eosin-stained specimens of liver, obtained in somes, the Golgi apparatus, mitochondria, and patients D.T. and J.F. after steroid administration other cytoplasmic organelles appeared unaltered.
revealed normal appearing liver cells except for a
Liver function tests performed in each patient pale, pink, vacuolar, cytoplasmic inclusion without between days 7 and 10 of steroid administration a membranous limit. Exposure of the tissue sec-were normal except for the following. The serum tions to ammonia fumes resulted in appearance of bilirubin concentration was 1.4 mg per 100 ml (1.1 a purple color with an absorption maximum of mg per 100 ml direct reacting) in patient J.V. 580 mix. This is the absorption maximum for The serum bilirubin concentration was 1.6 mg per BSP (7). These biopsy specimens were ob-100 ml (1.2 mg per 100 ml direct reacting) in patained within 24 hours after the second BSP in-tient J.L. The serum glutamic oxaloacetic transfusion study, and the vacuolar inclusions within aminase activity was 85,u in patient A.M. Liver 
DISCUSSION
The observed reduction in hepatic Tm for BSP with normal relative hepatic storage of BSP in patients receiving 177a-ethyl-19-nortestosterone could result from a deficiency in hepatic glutathione, reduced activity of the enzyme which catalyzes the formation of BSP glutathione, or an abnormality in hepatic parenchymal cell excretory function, or all. Because BSP was retained in plasma primarily as a conjugate after steroid administration, it is unlikely that there is a limitation in either hepatic glutathione content or activity of the conjugating enzyme in man. In rats, steroid administration in comparable doses does not decrease either hepatic glutathione content or conjugating enzyme activity (12) . These observations are most consistent with the conclusion that 17a-ethyl-19-nortestosterone interferes with the transport of BSP from the liver cell into the bile. This effect of the steroid may prove useful in the biochemical study of the normal mechanism and regulation of excretory transport by the liver cell.
Philp, Grodsky, and Carbone (10) and Combes (11) have demonstrated that the formation of conjugated BSP is a major determinant of the maximal rate at which BSP is excreted from the liver cell into the bile. The fact that BSP is retained in plasma primarily as a conjugate in patients treated with 17a-ethyl-19-nortestosterone supports this conclusion.
Heaney and Whedon (13) some of the difficulties of single injection experiments, as BSP storage and Tm can be quantitatively estimated. In a study of BSP metabolism in patients with hepatitis, cirrhosis, biliary obstruction, and jaundice after chlorpromazine administration, both BSP storage and Tm were reduced (9) . The functional abnormality observed after administration of 17a-ethyl-19-nortestosterone in this study is similar to that seen in patients with chronic familial nonhemolytic jaundice with conjugated bilirubin in the serum with and without an unidentified pigment in the liver cells, in whom hepatic storage of BSP is normal, BSP Tm is reduced virtually to zero (9, 15) , and BSP is retained in the plasma primarily as a conjugate (16) . An inherited abnormality in the transfer of conjugated bilirubin and other substances from the liver cell into the bile has been postulated to explain this syndrome (15, 17) .
Carbone, Grodsky, and Hjelte (18) demonstrated that after administration of 17-methyltestosterone to normal subjects, BSP is retained in plasma primarily as a conjugate. The effects observed with 17ac-ethyl-19-nortestosterone in the present study may, therefore, be produced by other steroids of similar structure.
Alterations in hepatic cell membrane staining reactions and absent bile canalicular microvilli have been described in rats (19, 20) and humans (2) after administration of 17a-ethyl-19-nortestosterone. In this study, in two patients, the functional abnormality in BSP metabolism was observed without significant alterations in liver cell ultrastructure or histochemical staining reactions. This observation suggests that the previously de- scribed structural abnormalities may not be etiologically related to the functional defect. These studies suggest that 17a-ethyl-19-nortestosterone interferes with the transfer of BSP conjugates from the liver cell into the bile.
